No Data
Hengrui received an FDA warning letter | Jianzhi Research
A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.
Hengrui's FORM 483 is not that simple | Jianzhi Research
According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.
Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research
Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.
With demand remaining consistent, computing leader Haiguang Information saw a year-on-year net profit growth of 38% in the first three quarters. | Financial report insights
In the third quarter, Haiguang Information's revenue increased by 3.3% year-on-year, and net income attributable to shareholders increased by 27.23% year-on-year. Analysis suggests that continuous iteration of products is expected to consolidate the company's leading position and help improve profitability.
People who lose weight aren't in a hurry; are pharmaceutical companies in a hurry? The chairman of Borui Pharmaceutical claims to have “tried drugs on his own” to lose 30 pounds or is mired in controversy
Insane.
Huahai Pharmaceutical's refinancing bets on 100 tons of COVID-19 drugs: disputes over economic benefits still exist
In the context of tightening refinancing, the rationality and necessity of refinancing for A-share companies has received widespread attention from the market. Recently, Huahai Pharmaceutical (600521.SH) updated the refinancing inquiry response materials. Among them, the issue of the rationality of estimating the economic benefits of the production expansion plan attracted the attention of the regulatory authorities. According to the application materials, Huahai Pharmaceutical plans to raise 1,560 billion yuan to invest in the construction of “digital intelligent manufacturing of formulations”, “multi-functional production platform for specialty APIs such as antiviruses” projects, and supplementary liquidity. Among them, the “Multifunctional Production Platform for Antiviral and Other Special APIs” project involves “an annual output of 100 tons